Share Price and Basic Stock Data
Last Updated: November 28, 2025, 10:21 am
| PEG Ratio | -3.81 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Aspira Pathlab & Diagnostics Ltd operates within the Hospitals & Medical Services industry, focusing on pathology and diagnostic services. As of the latest data, the company’s stock price stood at ₹66.90, with a market capitalization of ₹68.90 Cr. The revenue trend exhibits fluctuations, with sales recorded at ₹14.46 Cr in FY 2023, a decline from ₹19.54 Cr in FY 2022. However, a positive trajectory is visible in the trailing twelve months (TTM) figures, reaching ₹24.53 Cr. Quarterly sales showed variability, peaking at ₹4.64 Cr in June 2024 before declining to ₹2.60 Cr in June 2023. The sales growth in subsequent quarters, especially the rise to ₹6.18 Cr in September 2024, indicates potential recovery and expansion. This variability may be attributed to seasonal demand for diagnostic services and operational adjustments. Overall, while the company faces challenges, the recent trends suggest a strategic pivot towards a more robust revenue generation phase.
Profitability and Efficiency Metrics
The profitability metrics of Aspira Pathlab present a mixed picture. The operating profit margin (OPM) in FY 2023 stood at 11.07%, a decrease from 32.65% in FY 2022, reflecting rising costs and operational challenges. In the most recent quarter, June 2025, the OPM improved to 15.43%, suggesting a recovery in operational efficiency. Net profit for FY 2025 reported at ₹2.07 Cr, translating to an earnings per share (EPS) of ₹2.01, further indicating a rebound from the losses seen in previous periods. The interest coverage ratio (ICR) was a strong 11.27x, highlighting the company’s capability to meet interest obligations comfortably. Additionally, the cash conversion cycle (CCC) stood at 16.30 days, which is favorable compared to typical industry standards, indicating efficient management of working capital. However, the declining trend in OPM raises concerns about cost management and pricing strategies that need addressing to sustain profitability.
Balance Sheet Strength and Financial Ratios
Aspira Pathlab’s balance sheet reflects a stable financial position with no reported borrowings, demonstrating a conservative financing approach. The company has a price-to-book value (P/BV) of 7.21x, which indicates that the market values the company at a premium relative to its book value. The return on equity (ROE) stood impressively at 33.6%, showcasing effective utilization of shareholders’ equity to generate profits. Furthermore, the return on capital employed (ROCE) at 17.4% suggests efficient capital utilization in generating operational profits. The current ratio of 2.26x and quick ratio of 2.05x indicate strong liquidity, providing a buffer against short-term obligations. However, the absence of reserves and borrowings can limit financial flexibility in pursuing growth opportunities or weathering downturns. Overall, while the financial ratios reflect stability, the company’s reliance on equity financing may constrain growth initiatives.
Shareholding Pattern and Investor Confidence
Aspira Pathlab’s shareholding pattern reveals a significant public stake of 81.61%, indicating strong retail investor interest. Promoter holdings have gradually decreased to 18.39%, which may raise questions about long-term commitment and confidence in the company’s growth trajectory. The number of shareholders has increased to 1,755, reflecting growing interest among individual investors. However, the absence of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) suggests limited institutional confidence, which can impact the stock’s liquidity and price stability. The steady decline in promoter holdings could also signal a lack of confidence or strategic realignment. Maintaining a robust communication strategy with shareholders will be essential to bolster confidence and attract institutional investments. Overall, while the public’s interest is a positive sign, the increasing public share and declining promoter stake may require careful management to sustain investor trust.
Outlook, Risks, and Final Insight
The outlook for Aspira Pathlab appears cautiously optimistic, contingent upon stabilizing revenue and improving profitability metrics. The positive quarterly sales trends indicate potential recovery; however, operational efficiencies must be enhanced to sustain growth. Key risks include ongoing fluctuations in operating margins and the reliance on a predominantly public shareholder base, which may lead to volatility in stock performance. Additionally, the absence of institutional investors could hinder long-term strategic initiatives. To navigate these challenges, the company should focus on cost management, innovative service offerings, and strengthening relationships with institutional investors. If successful, Aspira Pathlab could leverage its strong ROE and liquidity position to capitalize on growth opportunities in the expanding healthcare sector. Conversely, failure to address operational inefficiencies and market confidence may impede its recovery trajectory, necessitating strategic pivots to ensure sustainable growth.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Aspira Pathlab & Diagnostics Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| NG Industries Ltd | 43.0 Cr. | 128 | 195/125 | 8.79 | 117 | 2.72 % | 23.6 % | 20.7 % | 10.0 |
| Global Longlife Hospital and Research Ltd | 20.2 Cr. | 19.2 | 35.5/18.3 | 24.3 | 0.00 % | 13.7 % | 17.7 % | 10.0 | |
| Gian Lifecare Ltd | 11.6 Cr. | 11.2 | 21.4/11.2 | 128 | 19.1 | 0.00 % | 3.00 % | 0.81 % | 10.0 |
| Fortis Malar Hospitals Ltd | 120 Cr. | 63.8 | 98.7/53.6 | 26.4 | 18.3 | 0.00 % | 0.83 % | 0.56 % | 10.0 |
| Family Care Hospitals Ltd | 20.6 Cr. | 3.81 | 7.60/3.40 | 1.51 | 0.00 % | 79.2 % | 85.5 % | 10.0 | |
| Industry Average | 27,787.29 Cr | 790.25 | 98.90 | 99.39 | 0.32% | 15.48% | 14.81% | 9.04 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2.97 | 3.71 | 4.37 | 3.41 | 2.60 | 3.32 | 3.46 | 3.82 | 4.64 | 6.18 | 5.41 | 5.78 | 5.25 |
| Expenses | 2.79 | 3.25 | 3.56 | 3.26 | 2.92 | 3.68 | 3.83 | 3.95 | 4.29 | 4.83 | 4.65 | 4.73 | 4.44 |
| Operating Profit | 0.18 | 0.46 | 0.81 | 0.15 | -0.32 | -0.36 | -0.37 | -0.13 | 0.35 | 1.35 | 0.76 | 1.05 | 0.81 |
| OPM % | 6.06% | 12.40% | 18.54% | 4.40% | -12.31% | -10.84% | -10.69% | -3.40% | 7.54% | 21.84% | 14.05% | 18.17% | 15.43% |
| Other Income | 0.06 | 0.07 | 0.12 | 0.07 | 0.10 | 0.14 | 0.10 | 0.08 | 0.09 | 0.08 | 0.09 | 0.13 | 0.11 |
| Interest | 0.11 | 0.11 | 0.10 | 0.10 | 0.10 | 0.10 | 0.09 | 0.08 | 0.08 | 0.08 | 0.09 | 0.09 | 0.09 |
| Depreciation | 0.42 | 0.40 | 0.39 | 0.38 | 0.39 | 0.39 | 0.38 | 0.38 | 0.38 | 0.36 | 0.39 | 0.37 | 0.37 |
| Profit before tax | -0.29 | 0.02 | 0.44 | -0.26 | -0.71 | -0.71 | -0.74 | -0.51 | -0.02 | 0.99 | 0.37 | 0.72 | 0.46 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit | -0.29 | 0.02 | 0.44 | -0.26 | -0.72 | -0.71 | -0.74 | -0.50 | -0.02 | 0.99 | 0.38 | 0.72 | 0.47 |
| EPS in Rs | -0.28 | 0.02 | 0.43 | -0.25 | -0.70 | -0.69 | -0.72 | -0.49 | -0.02 | 0.96 | 0.37 | 0.70 | 0.46 |
Last Updated: August 19, 2025, 11:05 pm
Below is a detailed analysis of the quarterly data for Aspira Pathlab & Diagnostics Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 5.25 Cr.. The value appears to be declining and may need further review. It has decreased from 5.78 Cr. (Mar 2025) to 5.25 Cr., marking a decrease of 0.53 Cr..
- For Expenses, as of Jun 2025, the value is 4.44 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 4.73 Cr. (Mar 2025) to 4.44 Cr., marking a decrease of 0.29 Cr..
- For Operating Profit, as of Jun 2025, the value is 0.81 Cr.. The value appears to be declining and may need further review. It has decreased from 1.05 Cr. (Mar 2025) to 0.81 Cr., marking a decrease of 0.24 Cr..
- For OPM %, as of Jun 2025, the value is 15.43%. The value appears to be declining and may need further review. It has decreased from 18.17% (Mar 2025) to 15.43%, marking a decrease of 2.74%.
- For Other Income, as of Jun 2025, the value is 0.11 Cr.. The value appears to be declining and may need further review. It has decreased from 0.13 Cr. (Mar 2025) to 0.11 Cr., marking a decrease of 0.02 Cr..
- For Interest, as of Jun 2025, the value is 0.09 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.09 Cr..
- For Depreciation, as of Jun 2025, the value is 0.37 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.37 Cr..
- For Profit before tax, as of Jun 2025, the value is 0.46 Cr.. The value appears to be declining and may need further review. It has decreased from 0.72 Cr. (Mar 2025) to 0.46 Cr., marking a decrease of 0.26 Cr..
- For Tax %, as of Jun 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00%.
- For Net Profit, as of Jun 2025, the value is 0.47 Cr.. The value appears to be declining and may need further review. It has decreased from 0.72 Cr. (Mar 2025) to 0.47 Cr., marking a decrease of 0.25 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.46. The value appears to be declining and may need further review. It has decreased from 0.70 (Mar 2025) to 0.46, marking a decrease of 0.24.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 3:53 am
| Metric | Mar 2012 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.00 | 0.76 | 4.36 | 7.64 | 8.42 | 15.21 | 19.54 | 14.46 | 13.20 | 22.00 | 24.53 |
| Expenses | 0.02 | 0.14 | 0.23 | 3.34 | 8.24 | 10.88 | 10.25 | 11.69 | 13.16 | 12.86 | 14.38 | 18.44 | 19.72 |
| Operating Profit | -0.02 | -0.14 | -0.23 | -2.58 | -3.88 | -3.24 | -1.83 | 3.52 | 6.38 | 1.60 | -1.18 | 3.56 | 4.81 |
| OPM % | -339.47% | -88.99% | -42.41% | -21.73% | 23.14% | 32.65% | 11.07% | -8.94% | 16.18% | 19.61% | |||
| Other Income | 0.02 | 0.21 | 0.32 | 0.31 | 0.22 | 0.25 | 0.29 | 0.20 | 0.09 | 0.32 | 0.42 | 0.36 | 0.47 |
| Interest | 0.00 | 0.00 | 0.05 | 0.26 | 0.80 | 0.96 | 1.01 | 0.89 | 0.37 | 0.42 | 0.37 | 0.35 | 0.37 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.20 | 1.12 | 1.23 | 1.66 | 1.44 | 1.64 | 1.59 | 1.54 | 1.49 | 1.53 |
| Profit before tax | 0.00 | 0.07 | 0.04 | -2.73 | -5.58 | -5.18 | -4.21 | 1.39 | 4.46 | -0.09 | -2.67 | 2.08 | 3.38 |
| Tax % | 57.14% | 25.00% | 0.00% | 0.00% | 0.00% | 0.71% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||
| Net Profit | 0.00 | 0.02 | 0.03 | -2.72 | -5.58 | -5.18 | -4.24 | 1.38 | 4.46 | -0.09 | -2.67 | 2.07 | 3.41 |
| EPS in Rs | 0.00 | 0.09 | 0.13 | -5.24 | -10.75 | -6.32 | -4.56 | 1.34 | 4.33 | -0.09 | -2.59 | 2.01 | 3.32 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 50.00% | -9166.67% | -105.15% | 7.17% | 18.15% | 132.55% | 223.19% | -102.02% | -2866.67% | 177.53% |
| Change in YoY Net Profit Growth (%) | 0.00% | -9216.67% | 9061.52% | 112.32% | 10.98% | 114.40% | 90.64% | -325.21% | -2764.65% | 3044.19% |
Aspira Pathlab & Diagnostics Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2015-2016 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 21% |
| 3 Years: | 4% |
| TTM: | 48% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 59% |
| 5 Years: | 20% |
| 3 Years: | -23% |
| TTM: | 230% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 26% |
| 3 Years: | 13% |
| 1 Year: | 99% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 17% |
| 3 Years: | -3% |
| Last Year: | 24% |
Last Updated: September 5, 2025, 2:26 pm
No data available for the Balance Sheet data table.
Cash Flow
| Month | Mar 2012 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Financial Efficiency Indicators
| Month | Mar 2012 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 43.22 | 29.30 | 38.22 | 26.01 | 40.80 | 83.87 | 59.07 | 61.94 | 38.99 | |||
| Inventory Days | 312.86 | 103.88 | 45.22 | 51.36 | 51.35 | 46.50 | 58.40 | 62.69 | 50.31 | |||
| Days Payable | 730.00 | 64.58 | 46.84 | 73.37 | 91.60 | 70.91 | 51.10 | 101.70 | 73.00 | |||
| Cash Conversion Cycle | -373.92 | 68.61 | 36.60 | 4.00 | 0.55 | 59.46 | 66.37 | 22.93 | 16.30 | |||
| Working Capital Days | -2,199.61 | -5.86 | -96.03 | -127.01 | 16.32 | 69.30 | 48.72 | 25.16 | 14.10 | |||
| ROCE % | 0.00% | 1.82% | -25.39% | -38.41% | -34.49% | -25.15% | 19.77% | 35.65% | 2.01% | -15.87% | 17.37% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 |
|---|---|
| FaceValue | 10.00 |
| Basic EPS (Rs.) | 1.97 |
| Diluted EPS (Rs.) | 1.97 |
| Cash EPS (Rs.) | 3.46 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 11.82 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 11.82 |
| Revenue From Operations / Share (Rs.) | 21.37 |
| PBDIT / Share (Rs.) | 3.80 |
| PBIT / Share (Rs.) | 2.35 |
| PBT / Share (Rs.) | 2.01 |
| Net Profit / Share (Rs.) | 2.01 |
| NP After MI And SOA / Share (Rs.) | 1.97 |
| PBDIT Margin (%) | 17.79 |
| PBIT Margin (%) | 11.00 |
| PBT Margin (%) | 9.42 |
| Net Profit Margin (%) | 9.42 |
| NP After MI And SOA Margin (%) | 9.19 |
| Return on Networth / Equity (%) | 16.62 |
| Return on Capital Employeed (%) | 16.03 |
| Return On Assets (%) | 11.58 |
| Long Term Debt / Equity (X) | 0.09 |
| Total Debt / Equity (X) | 0.09 |
| Current Ratio (X) | 2.26 |
| Quick Ratio (X) | 2.05 |
| Interest Coverage Ratio (X) | 11.27 |
| Interest Coverage Ratio (Post Tax) (X) | 6.97 |
| Enterprise Value (Cr.) | 86.79 |
| EV / Net Operating Revenue (X) | 3.95 |
| EV / EBITDA (X) | 22.18 |
| MarketCap / Net Operating Revenue (X) | 3.99 |
| Price / BV (X) | 7.21 |
| Price / Net Operating Revenue (X) | 3.99 |
| EarningsYield | 0.02 |
After reviewing the key financial ratios for Aspira Pathlab & Diagnostics Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. No previous period data is available for comparison.
- For Basic EPS (Rs.), as of Mar 25, the value is 1.97. This value is below the healthy minimum of 5. No previous period data is available for comparison.
- For Diluted EPS (Rs.), as of Mar 25, the value is 1.97. This value is below the healthy minimum of 5. No previous period data is available for comparison.
- For Cash EPS (Rs.), as of Mar 25, the value is 3.46. This value is within the healthy range. No previous period data is available for comparison.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 11.82. No previous period data is available for comparison.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 11.82. No previous period data is available for comparison.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 21.37. No previous period data is available for comparison.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 3.80. This value is within the healthy range. No previous period data is available for comparison.
- For PBIT / Share (Rs.), as of Mar 25, the value is 2.35. This value is within the healthy range. No previous period data is available for comparison.
- For PBT / Share (Rs.), as of Mar 25, the value is 2.01. This value is within the healthy range. No previous period data is available for comparison.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 2.01. This value is within the healthy range. No previous period data is available for comparison.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 1.97. This value is below the healthy minimum of 2. No previous period data is available for comparison.
- For PBDIT Margin (%), as of Mar 25, the value is 17.79. This value is within the healthy range. No previous period data is available for comparison.
- For PBIT Margin (%), as of Mar 25, the value is 11.00. This value is within the healthy range. No previous period data is available for comparison.
- For PBT Margin (%), as of Mar 25, the value is 9.42. This value is below the healthy minimum of 10. No previous period data is available for comparison.
- For Net Profit Margin (%), as of Mar 25, the value is 9.42. This value is within the healthy range. No previous period data is available for comparison.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 9.19. This value is within the healthy range. No previous period data is available for comparison.
- For Return on Networth / Equity (%), as of Mar 25, the value is 16.62. This value is within the healthy range. No previous period data is available for comparison.
- For Return on Capital Employeed (%), as of Mar 25, the value is 16.03. This value is within the healthy range. No previous period data is available for comparison.
- For Return On Assets (%), as of Mar 25, the value is 11.58. This value is within the healthy range. No previous period data is available for comparison.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.09. This value is below the healthy minimum of 0.2. No previous period data is available for comparison.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.09. This value is within the healthy range. No previous period data is available for comparison.
- For Current Ratio (X), as of Mar 25, the value is 2.26. This value is within the healthy range. No previous period data is available for comparison.
- For Quick Ratio (X), as of Mar 25, the value is 2.05. This value exceeds the healthy maximum of 2. No previous period data is available for comparison.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 11.27. This value is within the healthy range. No previous period data is available for comparison.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 6.97. This value is within the healthy range. No previous period data is available for comparison.
- For Enterprise Value (Cr.), as of Mar 25, the value is 86.79. No previous period data is available for comparison.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.95. This value exceeds the healthy maximum of 3. No previous period data is available for comparison.
- For EV / EBITDA (X), as of Mar 25, the value is 22.18. This value exceeds the healthy maximum of 15. No previous period data is available for comparison.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.99. This value exceeds the healthy maximum of 3. No previous period data is available for comparison.
- For Price / BV (X), as of Mar 25, the value is 7.21. This value exceeds the healthy maximum of 3. No previous period data is available for comparison.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.99. This value exceeds the healthy maximum of 3. No previous period data is available for comparison.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. No previous period data is available for comparison.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Aspira Pathlab & Diagnostics Ltd:
- Net Profit Margin: 9.42%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 16.03% (Industry Average ROCE: 15.48%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 16.62% (Industry Average ROE: 14.81%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 6.97
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.05
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 19.7 (Industry average Stock P/E: 98.9)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.09
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 9.42%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | Flat No.2, R.D. Shah Building, Mumbai Maharashtra 400086 | info@aspiradiagnostics.com http://www.aspiradiagnostics.com |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Haseeb Drabu | Chairman & Ind.Director |
| Dr. Pankaj J Shah | Managing Director & CEO |
| Mr. Nikunj Mange | Executive Director |
| Mr. Manas Mengar | Independent Director |
| Mr. Avinash C Mahajan | Independent Director |
| Mrs. Mangala K Prabhu | Independent Director |